Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
35213036
DOI
10.1002/ijc.33980
Knihovny.cz E-zdroje
- Klíčová slova
- gallbladder cancer, hepatobiliary carcinoma, incidence trend, relative survival, risk factors,
- MeSH
- incidence MeSH
- lidé MeSH
- nádory žlučníku * epidemiologie etiologie MeSH
- oxid thoričitý * MeSH
- registrace MeSH
- věkové rozložení MeSH
- žlučové cesty extrahepatické * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Dánsko epidemiologie MeSH
- Finsko epidemiologie MeSH
- Norsko epidemiologie MeSH
- Švédsko epidemiologie MeSH
- Názvy látek
- oxid thoričitý * MeSH
Cancers of the gallbladder and extrahepatic bile ducts (called here "GBC" because gallbladder cancer is the main component) are rare in Europe, including the Nordic countries. Their incidence has varied for unknown reasons and we hypothesize that Thorotrast, a previously used carcinogenic radiographic contrast medium, has contributed to the incidence trends. We obtained incidence and survival data from the NORDCAN database, which includes cancer registry data from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE), which are globally the oldest national cancer databases, starting from 1943 in DK, 1953 in FI and NO and 1960 in SE, and extending to 2016. The incidence trend for GBC showed a broad maximum around 1980 in men (close to 3/100 000) and women (4/100 000), except for NO, where this phenomenon was not seen. In 1955, FI and NO incidence rates were equal but FI rates peaked and later declined similar to DK and SE rates. By 2010, the incidence was similar in all Nordic countries, for both men and women, at close to 2.0/100 000. Birth cohort analysis showed strong effects for countries other than NO. Relative 1-year survival increased for men from 20% to about 50% and similarly for women although at a 5 percentage points lower level. Survival in NO was better than in other countries in the 1980s. Thorotrast, causing a high risk of GBC, was extensively used in the Nordic countries between 1930 and end of 1940s, with the exception of NO, where these was no documented use. These data suggest that Thorotrast influenced GBC epidemiology and probably worsened survival in certain periods.
Biomedical Center Faculty of Medicine Charles University in Pilsen Pilsen Czech Republic
Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland
Department of Surgery University Hospital School of Medicine in Pilsen Pilsen Czech Republic
Department of Urology Helsinki University Hospital and University of Helsinki Helsinki Finland
Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany
Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany
Zobrazit více v PubMed
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet (London, England). 2021;397(10272):428-444.
Saika K, Matsuda T. Comparison of time trends in gallbladder cancer incidence (1973-1997) in East Asia, Europe and the USA, from Cancer Incidence in Five Continents Vols IV-VIII. Jpn J Clin Oncol. 2007;37(12):974-976.
Polednak A. Trends in cancer incidence in Connecticut, 1935-1991. Cancer. 1994;74:2863-2872.
Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99(11):895-897.
Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the United States-demographic and temporal variations by anatomic site. Int J Cancer. 2013;133(7):1664-1671.
Mjäland O, Adamsen S, Hjelmquist B, Ovaska J, Buanes T. Cholecystectomy rates, gallstone prevalence, and handling of bile duct injuries in Scandinavia. A comparative audit. Surg Endosc. 1998;12(12):1386-1389.
Noel R, Arnelo U, Lundell L, Sandblom G. Does the frequency of cholecystectomy affect the ensuing incidence of gallbladder cancer in Sweden? A population-based study with a 16-year coverage. World J Surg. 2016;40(1):66-72.
Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11(11):1478-1486. discussion 86-7.
Swank HA, Mulder IM, Hop WC, van de Vijver MJ, Lange JF, Bemelman WA. Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: a systematic review. Surg Endosc. 2013;27(12):4439-4448.
Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut. 2003;52:592-596.
Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36-46.
McGee EE, Jackson SS, Petrick JL, et al. Smoking, alcohol, and biliary tract cancer risk: a pooling project of 26 prospective studies. J Natl Cancer Inst. 2019;111(12):1263-1278.
McGee EE, Castro FA, Engels EA, et al. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. Int J Cancer. 2019;144(4):707-717.
IARC. Ionizing radiation, part 2: some internally deposited radionuclides. Views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 14-21 June 2000. IARC Monogr Eval Carcinog Risks Hum. 2001;78(Pt 2):1-559.
IARC. Radiation Lyon; Lyon, France: IARC; 2012:1-341.
Travis LB, Hauptmann M, Gaul LK, et al. Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiat Res. 2003;160(6):691-706.
Sternby Eilard M, Lundgren L, Cahlin C, Strandell A, Svanberg T, Sandström P. Surgical treatment for gallbladder cancer-a systematic literature review. Scand J Gastroenterol. 2017;52(5):505-514.
Lindnér P, Holmberg E, Hafström L. Gallbladder cancer-no improvement in survival over time in a Swedish population. Acta Oncol. 2018;57(11):1482-1489.
Engholm G, Ferlay J, Christensen N, et al. NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-736.
Zheng G, Sundquist K, Sundquist J, et al. Second primary cancers after liver, gallbladder and bile duct cancers, and these cancers as second primary cancers. Clin Epidemiol. 2021;13:683-691.
Storm HH, Klint A, Tryggvadóttir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):694-712.
Ji J, Sundquist K, Sundquist J, Hemminki K. Comparability of cancer identification among death registry, cancer registry and hospital discharge registry. Int J Cancer. 2012;131:2085-2093.
Teilum D. The prevalence of gallstones in autopsies from a Danish urban area. Frederiksberg 1914-1955. Acta Chir Scand. 1989;155(2):103-106.
Teilum D. Prevalence of gallstones at autopsy at the Institutes of Forensic Medicine in Aarhus and Copenhagen, Denmark, in 1944-1985. Scand J Gastroenterol. 1990;25(4):401-404.
Ahlberg J, Bergstrand LO, Sahlin S. Changes in gallstone morbidity in a community with decreasing frequency of cholecystectomies. A statistical study of the county of Stockholm, Sweden, 1969-1982. Acta Chir Scand Suppl. 1984;520:53-58.
Muhrbeck O, Sahlin S, Ahlberg J. Rise and fall in the number of cholecystectomies: Stockholm 1932-1993. Eur J Surg. 1996;162(3):199-204.
Andersson M, Juel K, Storm HH. Pattern of mortality among Danish thorotrast patients. J Clin Epidemiol. 1993;46(7):637-644.
Travis LB, Land CE, Andersson M, et al. Mortality after cerebral angiography with or without radioactive Thorotrast: an international cohort of 3,143 two-year survivors. Radiat Res. 2001;156(2):136-150.
IARC. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.
Matsuba T, Qiu D, Kurosawa M, et al. Overview of epidemiology of bile duct and gallbladder cancer focusing on the JACC study. J Epidemiol. 2005;15(Suppl 2):S150-S156.
Maqsudur Rashid A, Ramalingam L, Al-Jawadi A, Moustaid-Moussa N, Moussa H. Low dose radiation, inflammation, cancer and chemoprevention. Int J Radiat Biol. 2019;95(4):506-515.
Mousavi SM, Hemminki K. Cancer incidence, trends, and survival among immigrants to Sweden: a population-based study. Eur J Cancer Prev. 2015;24(Suppl 1):S1-s63.
Mori T, Fukutomi K, Kato Y, et al. 1998 results of the first series of follow-up studies on Japanese thorotrast patients and their relationships to an autopsy series. Radiat Res. 1999;152(6 Suppl):S72-S80.
Pukkala E, Martinsen JI, Lynge E, et al. Occupation and cancer-follow-up of 15 million people in five Nordic countries. Acta Oncol. 2009;48:646-790.
Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries-an overview of their procedures and data comparability. Acta Oncol. 2018;57:440-455.
